Cargando…
Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas
The improved knowledge of pathogenetic mechanisms underlying lymphomagenesis and the discovery of the critical role of tumor microenvironments have enabled the design of new drugs against cell targets and pathways. The Food and Drug Administration (FDA) has approved several monoclonal antibodies (mA...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558009/ https://www.ncbi.nlm.nih.gov/pubmed/31214498 http://dx.doi.org/10.3389/fonc.2019.00443 |
_version_ | 1783425535876005888 |
---|---|
author | Crisci, Stefania Di Francia, Raffaele Mele, Sara Vitale, Pasquale Ronga, Giuseppina De Filippi, Rosaria Berretta, Massimiliano Rossi, Paola Pinto, Antonio |
author_facet | Crisci, Stefania Di Francia, Raffaele Mele, Sara Vitale, Pasquale Ronga, Giuseppina De Filippi, Rosaria Berretta, Massimiliano Rossi, Paola Pinto, Antonio |
author_sort | Crisci, Stefania |
collection | PubMed |
description | The improved knowledge of pathogenetic mechanisms underlying lymphomagenesis and the discovery of the critical role of tumor microenvironments have enabled the design of new drugs against cell targets and pathways. The Food and Drug Administration (FDA) has approved several monoclonal antibodies (mAbs) and small molecule inhibitors (SMIs) for targeted therapy in hematology. This review focuses on the efficacy results of the currently available targeted agents and recaps the main ongoing trials in the setting of mature B-Cell non-Hodgkin lymphomas. The objective is to summarize the different classes of novel agents approved for mature B-cell lymphomas, to describe in synoptic tables the results they achieved and, finally, to draw future scenarios as we glimpse through the ongoing clinical trials. Characteristics and therapeutic efficacy are summarized for the currently approved mAbs [i.e., anti-Cluster of differentiation (CD) mAbs, immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and bispecific antibodies] as well as for SMIs i.e., inhibitors of B-cell receptor signaling, proteasome, mTOR BCL-2 HDAC pathways. The biological disease profiling of B-cell lymphoma subtypes may foster the discovery of innovative drug strategies for improving survival outcome in lymphoid neoplasms, as well as the trade-offs between efficacy and toxicity. The hope for clinical advantages should carefully be coupled with mindful awareness of the potential pitfalls and the occurrence of uneven, sometimes severe, toxicities. |
format | Online Article Text |
id | pubmed-6558009 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65580092019-06-18 Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas Crisci, Stefania Di Francia, Raffaele Mele, Sara Vitale, Pasquale Ronga, Giuseppina De Filippi, Rosaria Berretta, Massimiliano Rossi, Paola Pinto, Antonio Front Oncol Oncology The improved knowledge of pathogenetic mechanisms underlying lymphomagenesis and the discovery of the critical role of tumor microenvironments have enabled the design of new drugs against cell targets and pathways. The Food and Drug Administration (FDA) has approved several monoclonal antibodies (mAbs) and small molecule inhibitors (SMIs) for targeted therapy in hematology. This review focuses on the efficacy results of the currently available targeted agents and recaps the main ongoing trials in the setting of mature B-Cell non-Hodgkin lymphomas. The objective is to summarize the different classes of novel agents approved for mature B-cell lymphomas, to describe in synoptic tables the results they achieved and, finally, to draw future scenarios as we glimpse through the ongoing clinical trials. Characteristics and therapeutic efficacy are summarized for the currently approved mAbs [i.e., anti-Cluster of differentiation (CD) mAbs, immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and bispecific antibodies] as well as for SMIs i.e., inhibitors of B-cell receptor signaling, proteasome, mTOR BCL-2 HDAC pathways. The biological disease profiling of B-cell lymphoma subtypes may foster the discovery of innovative drug strategies for improving survival outcome in lymphoid neoplasms, as well as the trade-offs between efficacy and toxicity. The hope for clinical advantages should carefully be coupled with mindful awareness of the potential pitfalls and the occurrence of uneven, sometimes severe, toxicities. Frontiers Media S.A. 2019-06-04 /pmc/articles/PMC6558009/ /pubmed/31214498 http://dx.doi.org/10.3389/fonc.2019.00443 Text en Copyright © 2019 Crisci, Di Francia, Mele, Vitale, Ronga, De Filippi, Berretta, Rossi and Pinto. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Crisci, Stefania Di Francia, Raffaele Mele, Sara Vitale, Pasquale Ronga, Giuseppina De Filippi, Rosaria Berretta, Massimiliano Rossi, Paola Pinto, Antonio Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas |
title | Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas |
title_full | Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas |
title_fullStr | Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas |
title_full_unstemmed | Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas |
title_short | Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas |
title_sort | overview of targeted drugs for mature b-cell non-hodgkin lymphomas |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558009/ https://www.ncbi.nlm.nih.gov/pubmed/31214498 http://dx.doi.org/10.3389/fonc.2019.00443 |
work_keys_str_mv | AT criscistefania overviewoftargeteddrugsformaturebcellnonhodgkinlymphomas AT difranciaraffaele overviewoftargeteddrugsformaturebcellnonhodgkinlymphomas AT melesara overviewoftargeteddrugsformaturebcellnonhodgkinlymphomas AT vitalepasquale overviewoftargeteddrugsformaturebcellnonhodgkinlymphomas AT rongagiuseppina overviewoftargeteddrugsformaturebcellnonhodgkinlymphomas AT defilippirosaria overviewoftargeteddrugsformaturebcellnonhodgkinlymphomas AT berrettamassimiliano overviewoftargeteddrugsformaturebcellnonhodgkinlymphomas AT rossipaola overviewoftargeteddrugsformaturebcellnonhodgkinlymphomas AT pintoantonio overviewoftargeteddrugsformaturebcellnonhodgkinlymphomas |